According to UALCAN, such expression was lower in Caucasian cancer patients than in African-American and Asian ones, in N1 than in N2 and N3, in Stage II than in Stage III and IV cancer patients, in G2 than in G3 cancer patients, in adenocarcinoma than in squamous cell carcinoma patients, and in cancer patients without mutant p53 than in those with mutant p53 (Fig. 1D, p < 0.05). The gene discussed is TP53; the disease is adenocarcinoma.